A new therapeutic approach to treat psoriasis by inhibition of fatty acid oxidation by Etomoxir

British Journal of Dermatology

Volumn 153, Issue 5, 2005, Pages 937-944

  Caspary, F ^a   Elliott, G ^b   Nave B T ^a   Verzaal, P ^c   Rohrbach, M ^a   Das, P K ^d   Nagelkerken, L ^c   Nieland, J D ^a  

^a MediGene AG   (Germany)

^b Derphartox   (Netherlands)

^c TNO   (Netherlands)

^d ACADEMIC MEDICAL CENTER   (Netherlands)

Author keywords

Autoimmune disease; BNX transplanted skin model; Carnitine palmitoyltransferase 1; Etomoxir; Fat metabolism; Psoriasis

Indexed keywords

BETAMETHASONE; CARNITINE PALMITOYLTRANSFERASE; CARNITINE PALMITOYLTRANSFERASE INHIBITOR; ETOMOXIR; FATTY ACID;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL DIFFERENTIATION; CELL PROLIFERATION; CONTROLLED STUDY; DRUG EFFECT; DRUG TARGETING; ENZYME ACTIVITY; EPIDERMIS; EXAMINATION; FATTY ACID OXIDATION; FIBROBLAST CULTURE; HUMAN; HUMAN CELL; IMMUNE DEFICIENCY; KERATINOCYTE; MOUSE; NONHUMAN; NUDE MOUSE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN TARGETING; PSORIASIS; SKIN TRANSPLANTATION; SKINFOLD THICKNESS; TISSUE HOMOGENATE;

ANIMALS; CARNITINE O-PALMITOYLTRANSFERASE; CELL DIFFERENTIATION; CELL PROLIFERATION; CELLS, CULTURED; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME INHIBITORS; EPOXY COMPOUNDS; FATTY ACIDS; FIBROBLASTS; HUMANS; MICE; MICE, INBRED HRS; OXIDATION-REDUCTION; PSORIASIS; SKIN; SKIN TRANSPLANTATION; TRANSPLANTATION, HETEROLOGOUS;

EID: 27544484900     PISSN: 00070963     EISSN: 13652133     Source Type: Journal    
DOI: 10.1111/j.1365-2133.2005.06811.x     Document Type: Article

References (28)

1. Kanda N, Tani K, Enomoto U et al. The skin fungus-induced Th1- and Th2-related cytokine, chemokine and prostaglandin E2 production in peripheral blood mononuclear cells from patients with atopic dermatitis and psoriasis vulgaris. Clin Exp Allergy 2002; 32:1243-50.
2. Travers JB, Norris DA, Leung DY. The keratinocyte as a target for staphylococcal bacterial toxins. J Invest Dermatol Symp Proc 2001; 6:225-30.
3. Korzhova TP, Shyrobokov VP, Koliadenko VH et al. [Coxsackie B viral infection in the etiology and clinical pathogenesis of psoriasis]. Lik Sprava 2001; 3:54-8.
4. Davison SC, Allen MH, Mallon E et al. Contrasting patterns of streptococcal superantigen-induced T-cell proliferation in guttate vs. chronic plaque psoriasis. Br J Dermatol 2001; 145:245-51.
5. Ito T, Furukawa F. Psoriasis guttate acuta triggered by varicella zoster virus infection. Eur J Dermatol 2000; 10:226-7.
6. Noah PW. The role of microorganisms in psoriasis. Semin Dermatol 1990; 9:269-76.
7. Nickoloff BJ, Schröder JM, von den Driesch P et al. Is psoriasis a T-cell disease? Exp Dermatol 2000; 9:359-75.
8. Rosenberg EW, Noah PW, Skinner RB Jr. Psoriasis is a visible manifestation of the skin's defense against micro-organisms. J Dermatol 1994; 21:375-81.
9. Rosenberg EW, Noah PW, Skinner RB Jr. Microorganisms and psoriasis. J Natl Med Assoc 1994; 86:305-10.
10. Jacobs RA, Sly WS, Majerus PW. The regulation of fatty acid biosynthesis in human skin fibroblasts. J Biol Chem 1973; 248:1268-76.
11. Madsen P, Rasmussen HH, Leffers H et al. Molecular cloning and expression of a novel keratinocyte protein (psoriasis-associated fatty acid-binding protein [PA-FABP]) that is highly up-regulated in psoriatic skin and that shares similarity to fatty acid-binding proteins. J Invest Dermatol 1992; 99:299-305.
12. Masouye I, Saurat JH, Siegenthaler G. Epidermal fatty-acid-binding protein in psoriasis, basal and squamous cell carcinomas: an immunohistological study. Dermatology 1996; 192:208-13.
13. Wolf HP. Possible new therapeutic approach in diabetes mellitus by inhibition of carnitine palmitoyltransferase 1 (CPT1). Horm Metab Res Suppl 1992; 26:62-7.
14. Lebwohl M. Psoriasis. Lancet 2003; 361:1197-204.
15. Elliott GR, Hammer AH, Fasbender MJ et al. Wound healing using human skin transplanted onto athymic nude mice: a comparison of 'dry' and 'moist' wound healing. Agents Actions 1991; 32:122-4.
16. Elliott GR, Butter L, Das PK. Development of Xenotransplanted Human Skin for Studying Psoriasis. Dutch Immunology Society, 2004.
17. Wrone-Smith T, Nickoloff BJ. Dermal injection of immunocytes induces psoriasis. J Clin Invest 1996; 98:1878-87.
18. Declercq PE, Falck JR, Kuwajima M et al. Characterization of the mitochondrial carnitine palmitoyltransferase enzyme system. I. Use of inhibitors. J Biol Chem 1987; 262:9812-21.
19. McGarry JD, Brown NF. The mitochondrial carnitine palmitoyl-transferase system. From concept to molecular analysis. Eur J Biochem 1997; 244:1-14.
20. Zarain-Herzberg A, Rupp H. Therapeutic potential of CPT I inhibitors: cardiac gene transcription as a target. Expert Opin Invest Drugs 2002; 11:345-56.
21. Rosenberg EW, Noah PW, Skinner RB Jr. Animal models of psoriasis. J Invest Dermatol 1999; 113:427.
22. Schön MP. Animal models of psoriasis-what can we learn from them? J Invest Dermatol 1999; 112:405-10.
23. Koo J, Lebwohl M. Duration of remission of psoriasis therapies. J Am Acad Dermatol 1999; 41:51-9.
24. Mayser P, Grimm H, Grimminger F. n-3 fatty acids in psoriasis. Br J Nutr 2002; 87 (Suppl. 1):S77-82.
25. Gil A. Polyunsaturated fatty acids and inflammatory diseases. Biomed Pharmacother 2002; 56:388-96.
26. Friedman ES, LaNatra N, Stiller MJ. NSAIDs in dermatologic therapy: review and preview. J Cutan Med Surg 2002; 6:449-59.
27. Simopoulos AP. Omega-3 fatty acids in inflammation and autoimmune diseases. J Am Coll Nutr 2002; 21:495-505.
28. Lithell H, Bruce A, Gustafsson IB et al. A fasting and vegetarian diet treatment trial on chronic inflammatory disorders. Acta Derm Venereol (Stockh) 1983; 63:397-403.